TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32430459

Group type: EXPERIMENTAL
Intervention: Diabetes-related traits (including T2DM)
Number of subjects: 898130

Group type: EXPERIMENTAL
Intervention: Diabetes-related traits (including T1DM, T2DM)
Number of subjects: 898130

Group type: EXPERIMENTAL
Intervention: Other diseases/traits (including inflammatory bowel disease, breast cancer, lung cancer, asthma, smoking)
Number of subjects: 898130

Group type: EXPERIMENTAL
Intervention: Drugs (fostamatinib, zinc)
Number of subjects: 898130
Study: 36008574

Group type: EXPERIMENTAL
Intervention: Yttrium-90 (Y90) radioembolization with chemotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 60
Study: 34769814

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control (CTL)
Number of subjects: 157
Study: 35072717

Group type: COMPARATOR
Intervention: Information from electronic health care records
Number of subjects: 3543

Group type: EXPERIMENTAL
Intervention: Steps from applications on their phone
Number of subjects: 3543

Group type: EXPERIMENTAL
Intervention: Conjoint attributes
Number of subjects: 3543

Group type: EXPERIMENTAL
Intervention: Clusters of consumers based on willingness to share
Number of subjects: 3543
Study: 33432643

Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention (booklet and coaching on postoperative days 2, 3, and 7)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention
Number of subjects: 220
Study: 33463497

Group type: EXPERIMENTAL
Intervention: Early goal‐directed therapy (EGDT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ultrasound-guided fluid resuscitation
Number of subjects: 40
Study: 35941373

Group type: EXPERIMENTAL
Intervention: Pepinemab
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study: 33635156

Group type: EXPERIMENTAL
Intervention: eHealth program for hearing aid management
Number of subjects: 82

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 82
Study: 34684525

Group type: EXPERIMENTAL
Intervention: Salmon (246 g fillet/day for 8 weeks, 3 days per week)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Yellowstripe scad (385 g whole fish/day for 8 weeks, 3 days per week)
Number of subjects: 49
Study: 34090854

Group type: EXPERIMENTAL
Intervention: Self-paced, web-based transfer training module
Number of subjects: 72

Group type: COMPARATOR
Intervention: Waitlist control group (WLCG)
Number of subjects: 72
Study: 33263234

Group type: EXPERIMENTAL
Intervention: TLAe (20 mg/kg subcutaneous)
Number of subjects: 91

Group type: COMPARATOR
Intervention: CEF (125 mg/quarter intramammary)
Number of subjects: 91
Study: 33764324

Group type: EXPERIMENTAL
Intervention: Soy isoflavone 100 mg/d for 8 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 32464280

Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg once daily for 3 weeks on/1 week off
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 35179193

Group type: COMPARATOR
Intervention: Almonds (300 kcal/d)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: French fries (potato group, 300 kcal/d)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: French fries with herb/spices mix (potato + herb/spices group, 300 kcal/d)
Number of subjects: 180
Study: 33442242

Group type: EXPERIMENTAL
Intervention: Telemedication review (TMR)
Number of subjects: 16
Study: 32819304

Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Moderate-intensity, continuous aerobic training (CMIT)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Wait-list control (CON)
Number of subjects: 17
Study: 35737919

Group type: EXPERIMENTAL
Intervention: Durvalumab plus Olaparib (1,500 mg intravenously once every 4 weeks + 300 mg orally, twice daily)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Durvalumab plus Placebo
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Durvalumab plus Olaparib
Number of subjects: 154
Study: 33881748

Group type: EXPERIMENTAL
Intervention: 1RM-TRAIN
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: TRAD-TRAIN
Number of subjects: 151

Group type: COMPARATOR
Intervention: CONTROL
Number of subjects: 151
Study: 32828349

Group type: EXPERIMENTAL
Intervention: Training based on a Nursing Module on abuse among women with mental illness
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 68
Study: 36261594

Group type: EXPERIMENTAL
Intervention: Structured Water Dance Intervention (SWAN), administered for 40 minutes once a week during a 12-week period.
Number of subjects: 34
Study: 33839923

Group type: EXPERIMENTAL
Intervention: Anemia group (hemoglobin < 12 g/dL for women and < 13 g/dL for men)
Number of subjects: 1721

Group type: COMPARATOR
Intervention: Non-anemia group
Number of subjects: 1721
Study: 34647600

Group type: EXPERIMENTAL
Intervention: Males at 3 months (mean LAZ: -0.94) vs Females (mean LAZ: -0.74)
Number of subjects: 1084

Group type: EXPERIMENTAL
Intervention: Males at 3 months (mean WAZ: -0.63) vs Females (mean WAZ: -0.48)
Number of subjects: 1084

Group type: EXPERIMENTAL
Intervention: Males with illness at 3 months (ΔWAZ: -0.24) vs Females with illness (ΔWAZ: 0.03)
Number of subjects: 1084
Study: 34454674

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 749

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 749
Study: 32618212

Group type: EXPERIMENTAL
Intervention: Group Music (GM) - 30-minute musical intervention before chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group Music (GM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group Control (GC)
Number of subjects: 0
Study: 35703758

Group type: EXPERIMENTAL
Intervention: Tailored Motivational Interviewing (TMI)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Communities of practice guidance with or without internal facilitator support
Number of subjects: 151
Study: 33990120

Group type: EXPERIMENTAL
Intervention: CRC screening education intervention
Number of subjects: 0
Study: 33183668

Group type: EXPERIMENTAL
Intervention: PT + BT
Number of subjects: 270

Group type: COMPARATOR
Intervention: PT
Number of subjects: 270
Study: 35548423

Group type: EXPERIMENTAL
Intervention: Minimally invasive cardiac surgery-coronary artery bypass grafting (MICS-CABG)
Number of subjects: 248

Group type: COMPARATOR
Intervention: CABG (control group)
Number of subjects: 248
Study: 34560835

Group type: COMPARATOR
Intervention: Remifentanil plasma target concentration 0 ng/ml (Group R0)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Remifentanil plasma target concentration 1 ng/ml (Group R1)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Remifentanil plasma target concentration 2 ng/ml (Group R2)
Number of subjects: 52
Study: 35636696

Group type: EXPERIMENTAL
Intervention: Osimertinib plus Bevacizumab (80 mg daily + 15 mg/kg every 3 weeks)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Osimertinib monotherapy
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Osimertinib plus Bevacizumab
Number of subjects: 122
Study: 36156930

Group type: EXPERIMENTAL
Intervention: Nomogram risk prediction score for severity of AHTGP (referred to as AAP)
Number of subjects: 243
Study: 33079474

Group type: EXPERIMENTAL
Intervention: Nurse-led hypertension management program (20 weeks of health education and motivational meetings)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 74
Study: 37003126

Group type: EXPERIMENTAL
Intervention: Handgrip strength (HGS) measured using a dynamometer
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Bayley Scales of Infant Development‐III for neurodevelopment assessment
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Multiple regression analysis
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Maternal education level
Number of subjects: 116
Study: 34383312

Group type: COMPARATOR
Intervention: Ataluren
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deflazacort
Number of subjects: 0
Study: 32115998

Group type: EXPERIMENTAL
Intervention: Body diversity images
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Thin-ideal images
Number of subjects: 106
Study: 34995100

Group type: EXPERIMENTAL
Intervention: PRO-based symptom management
Number of subjects: 166

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 166
Study: 34682522

Group type: EXPERIMENTAL
Intervention: High Intensity Training (HIT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Moderate Intensity Training (MIT)
Number of subjects: 35
Study: 33125478

Group type: EXPERIMENTAL
Intervention: High insoluble fiber (ISF) diet
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High soluble fiber (SF) diet
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal level of dietary fiber (CON)
Number of subjects: 60
Study: 35020052

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 500 mg daily for 12 months
Number of subjects: 332

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 332
Study: 33522997

Group type: EXPERIMENTAL
Intervention: T2WI-derived MDF values
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: ADC-derived MDF values
Number of subjects: 85
Study: 35416981

Group type: EXPERIMENTAL
Intervention: Exendin-(9-39) 0.44 mg/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Exendin-(9-39) 0.6 mg/kg during MMTT
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Exendin-(9-39) 0.6 mg/kg during OPTT
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Exendin-(9-39) 0.6 mg/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Exendin-(9-39) during OPTT
Number of subjects: 16
Study: 32847444

Group type: EXPERIMENTAL
Intervention: Changweishu combined with routine Western medicine treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Routine Western medicine treatments (meropenem, noradrenaline, glutamine glue, Bifidobacterium lactis triple‐strain tablet)
Number of subjects: 50
Study: 35760724

Group type: EXPERIMENTAL
Intervention: Stratified exercise therapy (including dietary intervention for obesity subgroup)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Usual exercise therapy (control)
Number of subjects: 335
Study: 33910091

Group type: EXPERIMENTAL
Intervention: Technology Supported Mindfulness training (TSM) using the 'Muse' device for 8 weeks
Number of subjects: 71

Group type: COMPARATOR
Intervention: Wait list control for 8 weeks
Number of subjects: 71
Study: 35466705

Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to Occupational Performance intervention (one hour weekly for 10 weeks)
Number of subjects: 78
Study: 34525990

Group type: EXPERIMENTAL
Intervention: H2GO! intervention
Number of subjects: 450

Group type: COMPARATOR
Intervention: Usual care control (wait-list)
Number of subjects: 450
Study: 36203988

Group type: EXPERIMENTAL
Intervention: Modified Mediterranean Diet A (MMD A)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Modified Mediterranean Diet B (MMD B)
Number of subjects: 95
Study: 33471146

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg ketamine infusion
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine infusion
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 71
Study: 32091429

Group type: EXPERIMENTAL
Intervention: Prediction-based decision rule
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 35148626

Group type: EXPERIMENTAL
Intervention: Sterile polyacrylate wound pad with activated carbon cloth treatment
Number of subjects: 77

Group type: COMPARATOR
Intervention: Standard non-adhesive hydrocellular foam dressing with silver
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 77
Study: 34587943

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg plus ezetimibe 10 mg
Number of subjects: 101

Group type: COMPARATOR
Intervention: Rosuvastatin 20 mg
Number of subjects: 101
Study: 32728546

Group type: EXPERIMENTAL
Intervention: Budesonide nasal douching
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard postoperative regimen (Control)
Number of subjects: 60
Study: 35494521

Group type: EXPERIMENTAL
Intervention: Aqua astricta flushing (refrigerated normal saline)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Normal temperature saline (control)
Number of subjects: 185
Study: 32664145

Group type: EXPERIMENTAL
Intervention: Bushen Yisui and Ziyin Jiangzhuo (BYZJ) granules administered twice daily for 4 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (simulated granules) administered twice daily for 4 weeks
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Bushen Yisui and Ziyin Jiangzhuo (BYZJ) granules
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (simulated granules)
Number of subjects: 90
Study: 33555720

Group type: EXPERIMENTAL
Intervention: Acupressure (12 sessions over 4 weeks)
Number of subjects: 0
Study: 32055822

Group type: EXPERIMENTAL
Intervention: PF‐06412562 (3 mg twice daily)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: PF‐06412562 (15 mg twice daily)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: PF‐06412562 (3 mg twice daily) and PF‐06412562 (15 mg twice daily)
Number of subjects: 77
Study: 34864737

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (CTR, without training)
Number of subjects: 61
Study: 34004482

Group type: EXPERIMENTAL
Intervention: LDLMartin
Number of subjects: 6701

Group type: EXPERIMENTAL
Intervention: LDLSampson
Number of subjects: 6701

Group type: COMPARATOR
Intervention: LDLFriedewald
Number of subjects: 6701
Study: 32022990

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 100
Study: 35197189

Group type: EXPERIMENTAL
Intervention: Standardized delirium prevention and treatment measures
Number of subjects: 772

Group type: COMPARATOR
Intervention: No standardized delirium prevention and treatment measures (control)
Number of subjects: 772
Study: 34684351

Group type: EXPERIMENTAL
Intervention: Ginseng Extract 3 g
Number of subjects: 90

Group type: COMPARATOR
Intervention: Ginseng Extract 1 g
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 36058804

Group type: EXPERIMENTAL
Intervention: Photodynamic Diagnosis-guided Laser Photocoagulation of Bladder Tumor (PC-BT) in outpatient department using a 980 nm diode laser
Number of subjects: 206

Group type: COMPARATOR
Intervention: Transurethral Resection of Bladder Tumor (TUR-BT) in general anesthesia
Number of subjects: 206
Study: 33060549

Group type: EXPERIMENTAL
Intervention: Stroboscopic vision
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal vision (Control)
Number of subjects: 32
Study: 32655129

Group type: EXPERIMENTAL
Intervention: HDAC3 alteration via lentivirus vectors in GC cell line BGC-823/AGS
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: HDAC3 treatment in GC cells
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: FOXA2 binding to FTO gene promoter
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: FTO stabilization of MYC mRNA
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: In vivo animal study of GC cell tumorigenesis in nude mice
Number of subjects: 64
Study: 32121111

Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction
Number of subjects: 43

Group type: COMPARATOR
Intervention: Continuous energy restriction
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 43
Study: 35673804

Group type: EXPERIMENTAL
Intervention: Scalp acupuncture combined with rehabilitation treatment (SR group)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Rehabilitation treatment alone (RE group)
Number of subjects: 108
Study: 32322943

Group type: COMPARATOR
Intervention: Subchondral injection of MSCs (from iliac bone marrow concentrate), 20 cm3 volume (10 cc in tibia and 10 cc in femur), average 7800 MSCs/mL.
Number of subjects: 140

Group type: COMPARATOR
Intervention: Total knee arthroplasty (TKA) on one side (control group).
Number of subjects: 140
Study: 34231275

Group type: EXPERIMENTAL
Intervention: Ethics Quarter intervention (12 sessions of 15 minutes each over 6 weeks)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Standard organisational ethics structures (control group)
Number of subjects: 341
Study: 32484129

Group type: EXPERIMENTAL
Intervention: Improvised renal replacement therapy (ImpRRT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Continuous renal replacement therapy (CRRT)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ImpRRT
Number of subjects: 12

Group type: COMPARATOR
Intervention: CRRT
Number of subjects: 12
Study: 32957571

Group type: EXPERIMENTAL
Intervention: Quercetin (1000 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 16
Study: 35276922

Group type: EXPERIMENTAL
Intervention: High-quality, optimal protein diet (1.9 g·kg−1·d−1)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Adequate protein diet (1.2 g·kg−1·d−1)
Number of subjects: 6
Study: 34042954

Group type: EXPERIMENTAL
Intervention: Multiparametric magnetic resonance imaging-targeted biopsy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systematic transrectal ultrasonography biopsy
Number of subjects: 0
Study: 32096451

Group type: EXPERIMENTAL
Intervention: Paclitaxel-Coated Balloon (DCB)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Uncoated Balloon
Number of subjects: 88
Study: 35435467

Group type: EXPERIMENTAL
Intervention: Substituting non-irritants (water or milk)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Healthy eating
Number of subjects: 105
Study: 34330599

Group type: EXPERIMENTAL
Intervention: Glucantime®
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Glucantime® + Oral Tamoxifen
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Glucantime® + Topical Tamoxifen
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 33
Study: 33156688

Group type: EXPERIMENTAL
Intervention: Breast milk for oral care
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sodium bicarbonate solution for oral care
Number of subjects: 50
Study: 32683550

Group type: EXPERIMENTAL
Intervention: AI system for segmentation and quantification of COVID-19 lung regions
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Computed imaging biomarkers (portion of infection and average infection HU)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: AI system evaluating changes in infection volumes
Number of subjects: 204
Study: 33694338

Group type: EXPERIMENTAL
Intervention: OMT+BEMER
Number of subjects: 40

Group type: COMPARATOR
Intervention: OMT only
Number of subjects: 40

Group type: COMPARATOR
Intervention: BEMER only
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (light touch and sham)
Number of subjects: 40
Study: 32483675

Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Brinzolamide
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: 0.25% Betaxolol
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: 0.25% Timolol Gel
Number of subjects: 658

Group type: COMPARATOR
Intervention: 0.5% Timolol Gel
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 658

Group type: COMPARATOR
Intervention: Beta-blockers
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Carbonic Anhydrase Inhibitors (CAI)
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Prostaglandins
Number of subjects: 658
Study: 36283760

Group type: EXPERIMENTAL
Intervention: Patient-reported outcome measures intervention
Number of subjects: 779

Group type: COMPARATOR
Intervention: Control group (no patient-reported outcome measures)
Number of subjects: 779
Study: 33757513

Group type: EXPERIMENTAL
Intervention: Occlusal trauma plus moderate orthodontic forces group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Moderate orthodontic forces group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Occlusal trauma group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy pulp control group
Number of subjects: 40
Study: 36273314

Group type: EXPERIMENTAL
Intervention: 300 μg GCSF administered intrauterine with hCG injection
Number of subjects: 320

Group type: COMPARATOR
Intervention: Normal saline administered intrauterine with hCG injection
Number of subjects: 320
Study: 36361434

Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RT) for 24 weeks, 60 min per session, 2 sessions per week
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 30
Study: 32317122

Group type: EXPERIMENTAL
Intervention: Podcast with interpolated questions (n=68)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Podcast without interpolated questions (n=69)
Number of subjects: 137
Study: 36368750

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefixime 400 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 500 mg plus 2 g azithromycin
Number of subjects: 0
Study: 32620345

Group type: EXPERIMENTAL
Intervention: Aurai water propelled, heating Eye Massager (AEM) used twice a day for 2 weeks
Number of subjects: 15
Study: 32367059

Group type: COMPARATOR
Intervention: DRD1 rs686 G variant (GG homozygosity) in the study group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: HTR2A rs6313 TT homozygotes
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: HTR2A rs2770304 TT homozygous cases
Number of subjects: 100
Study: 34557465

Group type: EXPERIMENTAL
Intervention: Information on early childhood intervention (ECI) provided to parents (cases)
Number of subjects: 26

Group type: COMPARATOR
Intervention: No information on early childhood intervention (ECI) provided to parents (controls)
Number of subjects: 26